Oesophageal anomaly in a newborn after maternal exposure to mycofenolate mofetil

BMJ Case Rep. 2009:2009:bcr04.2009.1791. doi: 10.1136/bcr.04.2009.1791. Epub 2009 Sep 2.

Abstract

Pregnancy in women with lupus nephritis is associated with increased risk of fetal and maternal complications. The risk of poor outcome is higher if there are signs of disease activity at conception. The presence of hypertension and anti-phospholipid antibodies worsens the prognosis. There are very few therapeutic options in view of the threat of various congenital anomalies and associated comorbidities. Mycofenolate mofetil (MMF) is contraindicated during pregnancy due to risk of congenital anomalies and fetal loss. This is a case of a woman with membranous lupus nephritis, who went into partial remission with rituximab and became pregnant while on maintenance therapy with MMF. Due to lack of alternative options, she continued to be given MMF. She had a successful outcome in spite of the presence of the poor prognostic factors. The baby had asymptomatic non-communicating duplication of the oesophagus, which has never been reported before in association with MMF during pregnancy.